512 related articles for article (PubMed ID: 24576547)
1. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Yadlapati A; Groh C; Passman R
Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
3. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Kosiuk J; Koutalas E; Doering M; Sommer P; Rolf S; Breithardt OA; Nedios S; Dinov B; Hindricks G; Richter S; Bollmann A
Europace; 2014 Jul; 16(7):1028-32. PubMed ID: 24489073
[TBL] [Abstract][Full Text] [Related]
4. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
Femia G; Fetahovic T; Shetty P; Lee A
Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
[TBL] [Abstract][Full Text] [Related]
5. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
10. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation.
Saeed M; Rahman A; Afzal A; Agoston I; Jammula P; Birnbaum Y; Ware DL; Uretsky BF; Schwarz ER; Rosanio S
Int J Cardiol; 2006 Nov; 113(3):401-5. PubMed ID: 16822564
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
13. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Klein HH
Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
[TBL] [Abstract][Full Text] [Related]
14. Electrocardiographic markers of cardioversion success in patients with atrial fibrillation.
Al Aloul B; Adabag AS; Can I; Roukoz H; McClintock S; Benditt D; Tholakanahalli V
South Med J; 2009 Sep; 102(9):885-9. PubMed ID: 19668022
[TBL] [Abstract][Full Text] [Related]
15. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
16. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
17. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
[TBL] [Abstract][Full Text] [Related]
18. [Anticoagulation in atrial fibrillation: a new era has begun].
Moser M; Bode C
Hamostaseologie; 2012; 32(1):37-9. PubMed ID: 22124808
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
20. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?
Johansson AK; Juhlin T; Engdahl J; Lind S; Hagwall K; Rorsman C; Fodor E; Alenholt A; Paul Nordin A; Rosenqvist M; Frick M
Europace; 2015 Oct; 17(10):1514-7. PubMed ID: 26017466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
